Gland Pharma Limited (BSE: GLAND.BO) Stock Competitors & Peer Comparison
See GLAND.BO's competitors and their performance on the BSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for GLAND.BO and its BSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GLAND.BO | ₹2,820.40 | -0.11% | 465B | 41.15 | ₹68.54 | +0.71% |
| SUNPHARMA.NS | ₹1,902.40 | -0.08% | 4.6T | 36.95 | ₹51.48 | +0.84% |
| SUNPHARMA.BO | ₹1,900.90 | -0.01% | 4.6T | 37.27 | ₹51.00 | +0.84% |
| DIVISLAB.NS | ₹8,597.00 | +0.32% | 2.3T | 78.05 | ₹110.15 | +0.35% |
| DIVISLAB.BO | ₹8,550.00 | -0.43% | 2.3T | 77.59 | ₹110.19 | +0.35% |
| TORNTPHARM.BO | ₹4,880.50 | -2.29% | 1.9T | 74.06 | ₹65.90 | +0.78% |
| TORNTPHARM.NS | ₹4,896.50 | -2.17% | 1.9T | 73.37 | ₹66.74 | +0.78% |
| CIPLA.BO | ₹1,426.20 | +0.72% | 1.2T | 29.95 | ₹48.00 | +0.91% |
| CIPLA.NS | ₹1,432.20 | +0.72% | 1.2T | 34.49 | ₹41.69 | +0.91% |
| ZYDUSLIFE.BO | ₹1,120.00 | +1.01% | 1.1T | 26.38 | ₹42.46 | +0.09% |
Stock Comparison
Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA.NS)
GLAND.BO vs SUNPHARMA.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, SUNPHARMA.NS has a market cap of 4.6T. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while SUNPHARMA.NS trades at ₹1,902.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas SUNPHARMA.NS's P/E ratio is 36.95. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, GLAND.BO is more volatile compared to SUNPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check SUNPHARMA.NS's competition here
Sun Pharmaceutical Industries Limited (BSE: SUNPHARMA.BO)
GLAND.BO vs SUNPHARMA.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, SUNPHARMA.BO has a market cap of 4.6T. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while SUNPHARMA.BO trades at ₹1,900.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas SUNPHARMA.BO's P/E ratio is 37.27. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, GLAND.BO is more volatile compared to SUNPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check SUNPHARMA.BO's competition here
Divi's Laboratories Limited (NSE: DIVISLAB.NS)
GLAND.BO vs DIVISLAB.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, DIVISLAB.NS has a market cap of 2.3T. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while DIVISLAB.NS trades at ₹8,597.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas DIVISLAB.NS's P/E ratio is 78.05. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to DIVISLAB.NS's ROE of +0.18%. Regarding short-term risk, GLAND.BO is more volatile compared to DIVISLAB.NS. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check DIVISLAB.NS's competition here
Divi's Laboratories Limited (BSE: DIVISLAB.BO)
GLAND.BO vs DIVISLAB.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, DIVISLAB.BO has a market cap of 2.3T. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while DIVISLAB.BO trades at ₹8,550.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas DIVISLAB.BO's P/E ratio is 77.59. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to DIVISLAB.BO's ROE of +0.18%. Regarding short-term risk, GLAND.BO is more volatile compared to DIVISLAB.BO. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check DIVISLAB.BO's competition here
Torrent Pharmaceuticals Limited (BSE: TORNTPHARM.BO)
GLAND.BO vs TORNTPHARM.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, TORNTPHARM.BO has a market cap of 1.9T. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while TORNTPHARM.BO trades at ₹4,880.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas TORNTPHARM.BO's P/E ratio is 74.06. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to TORNTPHARM.BO's ROE of +0.20%. Regarding short-term risk, GLAND.BO is less volatile compared to TORNTPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check TORNTPHARM.BO's competition here
Torrent Pharmaceuticals Limited (NSE: TORNTPHARM.NS)
GLAND.BO vs TORNTPHARM.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, TORNTPHARM.NS has a market cap of 1.9T. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while TORNTPHARM.NS trades at ₹4,896.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas TORNTPHARM.NS's P/E ratio is 73.37. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to TORNTPHARM.NS's ROE of +0.20%. Regarding short-term risk, GLAND.BO is less volatile compared to TORNTPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check TORNTPHARM.NS's competition here
Cipla Limited (BSE: CIPLA.BO)
GLAND.BO vs CIPLA.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, CIPLA.BO has a market cap of 1.2T. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while CIPLA.BO trades at ₹1,426.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas CIPLA.BO's P/E ratio is 29.95. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to CIPLA.BO's ROE of +0.10%. Regarding short-term risk, GLAND.BO is more volatile compared to CIPLA.BO. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check CIPLA.BO's competition here
Cipla Limited (NSE: CIPLA.NS)
GLAND.BO vs CIPLA.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, CIPLA.NS has a market cap of 1.2T. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while CIPLA.NS trades at ₹1,432.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas CIPLA.NS's P/E ratio is 34.49. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to CIPLA.NS's ROE of +0.10%. Regarding short-term risk, GLAND.BO is more volatile compared to CIPLA.NS. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check CIPLA.NS's competition here
Zydus Lifesciences Limited (BSE: ZYDUSLIFE.BO)
GLAND.BO vs ZYDUSLIFE.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, ZYDUSLIFE.BO has a market cap of 1.1T. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while ZYDUSLIFE.BO trades at ₹1,120.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas ZYDUSLIFE.BO's P/E ratio is 26.38. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to ZYDUSLIFE.BO's ROE of +0.16%. Regarding short-term risk, GLAND.BO is more volatile compared to ZYDUSLIFE.BO. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check ZYDUSLIFE.BO's competition here
Zydus Lifesciences Limited (NSE: ZYDUSLIFE.NS)
GLAND.BO vs ZYDUSLIFE.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, ZYDUSLIFE.NS has a market cap of 1.1T. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while ZYDUSLIFE.NS trades at ₹1,120.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas ZYDUSLIFE.NS's P/E ratio is 26.22. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to ZYDUSLIFE.NS's ROE of +0.16%. Regarding short-term risk, GLAND.BO is more volatile compared to ZYDUSLIFE.NS. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check ZYDUSLIFE.NS's competition here
Lupin Limited (NSE: LUPIN.NS)
GLAND.BO vs LUPIN.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, LUPIN.NS has a market cap of 1T. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while LUPIN.NS trades at ₹2,201.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas LUPIN.NS's P/E ratio is 17.29. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to LUPIN.NS's ROE of +0.26%. Regarding short-term risk, GLAND.BO is more volatile compared to LUPIN.NS. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check LUPIN.NS's competition here
Lupin Limited (BSE: LUPIN.BO)
GLAND.BO vs LUPIN.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, LUPIN.BO has a market cap of 1T. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while LUPIN.BO trades at ₹2,193.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas LUPIN.BO's P/E ratio is 17.21. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to LUPIN.BO's ROE of +0.26%. Regarding short-term risk, GLAND.BO is more volatile compared to LUPIN.BO. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check LUPIN.BO's competition here
Dr. Reddy's Laboratories Limited (BSE: DRREDDY.BO)
GLAND.BO vs DRREDDY.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, DRREDDY.BO has a market cap of 987.2B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while DRREDDY.BO trades at ₹1,175.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas DRREDDY.BO's P/E ratio is 22.85. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to DRREDDY.BO's ROE of +0.09%. Regarding short-term risk, GLAND.BO is more volatile compared to DRREDDY.BO. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check DRREDDY.BO's competition here
Mankind Pharma Limited (NSE: MANKIND.NS)
GLAND.BO vs MANKIND.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, MANKIND.NS has a market cap of 984.6B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while MANKIND.NS trades at ₹2,384.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas MANKIND.NS's P/E ratio is 45.61. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, GLAND.BO is more volatile compared to MANKIND.NS. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check MANKIND.NS's competition here
Laurus Labs Limited (BSE: LAURUSLABS.BO)
GLAND.BO vs LAURUSLABS.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, LAURUSLABS.BO has a market cap of 979.7B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while LAURUSLABS.BO trades at ₹1,814.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas LAURUSLABS.BO's P/E ratio is 89.35. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to LAURUSLABS.BO's ROE of +0.21%. Regarding short-term risk, GLAND.BO is more volatile compared to LAURUSLABS.BO. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check LAURUSLABS.BO's competition here
Mankind Pharma Limited (BSE: MANKIND.BO)
GLAND.BO vs MANKIND.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, MANKIND.BO has a market cap of 979.5B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while MANKIND.BO trades at ₹2,372.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas MANKIND.BO's P/E ratio is 45.37. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, GLAND.BO is more volatile compared to MANKIND.BO. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check MANKIND.BO's competition here
Dr. Reddy's Laboratories Limited (NSE: DRREDDY.NS)
GLAND.BO vs DRREDDY.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, DRREDDY.NS has a market cap of 978.5B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while DRREDDY.NS trades at ₹1,174.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas DRREDDY.NS's P/E ratio is 29.58. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to DRREDDY.NS's ROE of +0.09%. Regarding short-term risk, GLAND.BO is more volatile compared to DRREDDY.NS. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check DRREDDY.NS's competition here
Laurus Labs Limited (NSE: LAURUSLABS.NS)
GLAND.BO vs LAURUSLABS.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, LAURUSLABS.NS has a market cap of 973.5B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while LAURUSLABS.NS trades at ₹1,802.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas LAURUSLABS.NS's P/E ratio is 88.94. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to LAURUSLABS.NS's ROE of +0.21%. Regarding short-term risk, GLAND.BO is more volatile compared to LAURUSLABS.NS. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check LAURUSLABS.NS's competition here
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS)
GLAND.BO vs AUROPHARMA.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, AUROPHARMA.NS has a market cap of 932.9B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while AUROPHARMA.NS trades at ₹1,621.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas AUROPHARMA.NS's P/E ratio is 25.33. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to AUROPHARMA.NS's ROE of +0.10%. Regarding short-term risk, GLAND.BO is more volatile compared to AUROPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check AUROPHARMA.NS's competition here
Aurobindo Pharma Limited (BSE: AUROPHARMA.BO)
GLAND.BO vs AUROPHARMA.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, AUROPHARMA.BO has a market cap of 931.7B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while AUROPHARMA.BO trades at ₹1,619.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas AUROPHARMA.BO's P/E ratio is 25.31. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to AUROPHARMA.BO's ROE of +0.10%. Regarding short-term risk, GLAND.BO is more volatile compared to AUROPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check AUROPHARMA.BO's competition here
Glenmark Pharmaceuticals Limited (BSE: GLENMARK.BO)
GLAND.BO vs GLENMARK.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, GLENMARK.BO has a market cap of 666.1B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while GLENMARK.BO trades at ₹2,306.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas GLENMARK.BO's P/E ratio is 36.21. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to GLENMARK.BO's ROE of +0.19%. Regarding short-term risk, GLAND.BO is more volatile compared to GLENMARK.BO. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check GLENMARK.BO's competition here
Glenmark Pharmaceuticals Limited (NSE: GLENMARK.NS)
GLAND.BO vs GLENMARK.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, GLENMARK.NS has a market cap of 654.1B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while GLENMARK.NS trades at ₹2,317.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas GLENMARK.NS's P/E ratio is 37.99. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to GLENMARK.NS's ROE of +0.19%. Regarding short-term risk, GLAND.BO is more volatile compared to GLENMARK.NS. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check GLENMARK.NS's competition here
Alkem Laboratories Limited (NSE: ALKEM.NS)
GLAND.BO vs ALKEM.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, ALKEM.NS has a market cap of 645.7B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while ALKEM.NS trades at ₹5,400.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas ALKEM.NS's P/E ratio is 29.89. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to ALKEM.NS's ROE of +0.16%. Regarding short-term risk, GLAND.BO is more volatile compared to ALKEM.NS. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check ALKEM.NS's competition here
Alkem Laboratories Limited (BSE: ALKEM.BO)
GLAND.BO vs ALKEM.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, ALKEM.BO has a market cap of 644.4B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while ALKEM.BO trades at ₹5,397.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas ALKEM.BO's P/E ratio is 29.91. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to ALKEM.BO's ROE of +0.16%. Regarding short-term risk, GLAND.BO is more volatile compared to ALKEM.BO. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check ALKEM.BO's competition here
Ipca Laboratories Limited (BSE: IPCALAB.BO)
GLAND.BO vs IPCALAB.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, IPCALAB.BO has a market cap of 488.3B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while IPCALAB.BO trades at ₹1,910.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas IPCALAB.BO's P/E ratio is 36.09. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to IPCALAB.BO's ROE of +0.16%. Regarding short-term risk, GLAND.BO is more volatile compared to IPCALAB.BO. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check IPCALAB.BO's competition here
Ipca Laboratories Limited (NSE: IPCALAB.NS)
GLAND.BO vs IPCALAB.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, IPCALAB.NS has a market cap of 484.9B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while IPCALAB.NS trades at ₹1,911.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas IPCALAB.NS's P/E ratio is 35.90. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to IPCALAB.NS's ROE of +0.16%. Regarding short-term risk, GLAND.BO is more volatile compared to IPCALAB.NS. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check IPCALAB.NS's competition here
Gland Pharma Limited (NSE: GLAND.NS)
GLAND.BO vs GLAND.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, GLAND.NS has a market cap of 465.1B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while GLAND.NS trades at ₹2,819.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas GLAND.NS's P/E ratio is 41.12. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to GLAND.NS's ROE of +0.11%. Regarding short-term risk, GLAND.BO is less volatile compared to GLAND.NS. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check GLAND.NS's competition here
Ajanta Pharma Limited (NSE: AJANTPHARM.NS)
GLAND.BO vs AJANTPHARM.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, AJANTPHARM.NS has a market cap of 454.7B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while AJANTPHARM.NS trades at ₹3,639.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas AJANTPHARM.NS's P/E ratio is 40.12. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, GLAND.BO is more volatile compared to AJANTPHARM.NS. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check AJANTPHARM.NS's competition here
Ajanta Pharma Limited (BSE: AJANTPHARM.BO)
GLAND.BO vs AJANTPHARM.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, AJANTPHARM.BO has a market cap of 454.2B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while AJANTPHARM.BO trades at ₹3,640.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas AJANTPHARM.BO's P/E ratio is 40.12. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, GLAND.BO is more volatile compared to AJANTPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check AJANTPHARM.BO's competition here
Suven Pharmaceuticals Limited (NSE: SUVENPHAR.NS)
GLAND.BO vs SUVENPHAR.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while SUVENPHAR.NS trades at ₹1,078.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to SUVENPHAR.NS's ROE of +0.05%. Regarding short-term risk, GLAND.BO is less volatile compared to SUVENPHAR.NS. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check SUVENPHAR.NS's competition here
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO)
GLAND.BO vs SUVENPHAR.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while SUVENPHAR.BO trades at ₹1,075.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to SUVENPHAR.BO's ROE of +0.16%. Regarding short-term risk, GLAND.BO is less volatile compared to SUVENPHAR.BO. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check SUVENPHAR.BO's competition here
J. B. Chemicals & Pharmaceuticals Limited (NSE: JBCHEPHARM.NS)
GLAND.BO vs JBCHEPHARM.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, JBCHEPHARM.NS has a market cap of 387.9B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while JBCHEPHARM.NS trades at ₹2,416.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas JBCHEPHARM.NS's P/E ratio is 52.07. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to JBCHEPHARM.NS's ROE of +0.19%. Regarding short-term risk, GLAND.BO is less volatile compared to JBCHEPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check JBCHEPHARM.NS's competition here
Emcure Pharmaceuticals Ltd. (NSE: EMCURE.NS)
GLAND.BO vs EMCURE.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, EMCURE.NS has a market cap of 353.4B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while EMCURE.NS trades at ₹1,863.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas EMCURE.NS's P/E ratio is 34.06. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to EMCURE.NS's ROE of +0.21%. Regarding short-term risk, GLAND.BO is more volatile compared to EMCURE.NS. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check EMCURE.NS's competition here
Neuland Laboratories Limited (BSE: NEULANDLAB.BO)
GLAND.BO vs NEULANDLAB.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, NEULANDLAB.BO has a market cap of 299.5B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while NEULANDLAB.BO trades at ₹23,294.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas NEULANDLAB.BO's P/E ratio is 59.22. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to NEULANDLAB.BO's ROE of +0.28%. Regarding short-term risk, GLAND.BO is less volatile compared to NEULANDLAB.BO. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check NEULANDLAB.BO's competition here
Neuland Laboratories Limited (NSE: NEULANDLAB.NS)
GLAND.BO vs NEULANDLAB.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, NEULANDLAB.NS has a market cap of 298.9B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while NEULANDLAB.NS trades at ₹23,301.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas NEULANDLAB.NS's P/E ratio is 59.07. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to NEULANDLAB.NS's ROE of +0.28%. Regarding short-term risk, GLAND.BO is more volatile compared to NEULANDLAB.NS. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check NEULANDLAB.NS's competition here
Piramal Pharma Limited (NSE: PPLPHARMA.NS)
GLAND.BO vs PPLPHARMA.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, PPLPHARMA.NS has a market cap of 283.1B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while PPLPHARMA.NS trades at ₹213.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas PPLPHARMA.NS's P/E ratio is -182.45. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to PPLPHARMA.NS's ROE of -0.04%. Regarding short-term risk, GLAND.BO is less volatile compared to PPLPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check PPLPHARMA.NS's competition here
Piramal Pharma Limited (BSE: PPLPHARMA.BO)
GLAND.BO vs PPLPHARMA.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, PPLPHARMA.BO has a market cap of 282.4B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while PPLPHARMA.BO trades at ₹213.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas PPLPHARMA.BO's P/E ratio is -182.35. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to PPLPHARMA.BO's ROE of -0.04%. Regarding short-term risk, GLAND.BO is less volatile compared to PPLPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check PPLPHARMA.BO's competition here
Piramal Enterprises Limited (NSE: PEL.NS)
GLAND.BO vs PEL.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while PEL.NS trades at ₹1,124.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to PEL.NS's ROE of +0.01%. Regarding short-term risk, GLAND.BO is less volatile compared to PEL.NS. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check PEL.NS's competition here
Granules India Limited (BSE: GRANULES.BO)
GLAND.BO vs GRANULES.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, GRANULES.BO has a market cap of 213.7B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while GRANULES.BO trades at ₹858.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas GRANULES.BO's P/E ratio is 32.83. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to GRANULES.BO's ROE of +0.16%. Regarding short-term risk, GLAND.BO is more volatile compared to GRANULES.BO. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check GRANULES.BO's competition here
Granules India Limited (NSE: GRANULES.NS)
GLAND.BO vs GRANULES.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, GRANULES.NS has a market cap of 212.6B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while GRANULES.NS trades at ₹858.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas GRANULES.NS's P/E ratio is 32.60. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to GRANULES.NS's ROE of +0.16%. Regarding short-term risk, GLAND.BO is more volatile compared to GRANULES.NS. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check GRANULES.NS's competition here
Caplin Point Laboratories Ltd. (BSE: CAPLIPOINT.BO)
GLAND.BO vs CAPLIPOINT.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, CAPLIPOINT.BO has a market cap of 192.5B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while CAPLIPOINT.BO trades at ₹2,563.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas CAPLIPOINT.BO's P/E ratio is 29.73. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to CAPLIPOINT.BO's ROE of +0.21%. Regarding short-term risk, GLAND.BO is more volatile compared to CAPLIPOINT.BO. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check CAPLIPOINT.BO's competition here
Caplin Point Laboratories Limited (NSE: CAPLIPOINT.NS)
GLAND.BO vs CAPLIPOINT.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, CAPLIPOINT.NS has a market cap of 192.3B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while CAPLIPOINT.NS trades at ₹2,560.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas CAPLIPOINT.NS's P/E ratio is 29.73. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, GLAND.BO is more volatile compared to CAPLIPOINT.NS. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check CAPLIPOINT.NS's competition here
AstraZeneca Pharma India Limited (NSE: ASTRAZEN.NS)
GLAND.BO vs ASTRAZEN.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, ASTRAZEN.NS has a market cap of 185.4B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while ASTRAZEN.NS trades at ₹7,415.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas ASTRAZEN.NS's P/E ratio is 98.86. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to ASTRAZEN.NS's ROE of +0.20%. Regarding short-term risk, GLAND.BO is more volatile compared to ASTRAZEN.NS. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check ASTRAZEN.NS's competition here
AstraZeneca Pharma India Limited (BSE: ASTRAZEN.BO)
GLAND.BO vs ASTRAZEN.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, ASTRAZEN.BO has a market cap of 185.4B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while ASTRAZEN.BO trades at ₹7,410.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas ASTRAZEN.BO's P/E ratio is 98.79. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to ASTRAZEN.BO's ROE of +0.20%. Regarding short-term risk, GLAND.BO is more volatile compared to ASTRAZEN.BO. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check ASTRAZEN.BO's competition here
Eris Lifesciences Limited (NSE: ERIS.NS)
GLAND.BO vs ERIS.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, ERIS.NS has a market cap of 184.1B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while ERIS.NS trades at ₹1,328.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas ERIS.NS's P/E ratio is 37.57. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to ERIS.NS's ROE of +0.19%. Regarding short-term risk, GLAND.BO is more volatile compared to ERIS.NS. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check ERIS.NS's competition here
Eris Lifesciences Limited (BSE: ERIS.BO)
GLAND.BO vs ERIS.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, ERIS.BO has a market cap of 183.8B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while ERIS.BO trades at ₹1,325.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas ERIS.BO's P/E ratio is 42.98. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to ERIS.BO's ROE of +0.19%. Regarding short-term risk, GLAND.BO is more volatile compared to ERIS.BO. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check ERIS.BO's competition here
Cohance Lifesciences Limited (NSE: COHANCE.NS)
GLAND.BO vs COHANCE.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, COHANCE.NS has a market cap of 181.9B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while COHANCE.NS trades at ₹463.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas COHANCE.NS's P/E ratio is 143.81. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to COHANCE.NS's ROE of +0.03%. Regarding short-term risk, GLAND.BO is less volatile compared to COHANCE.NS. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check COHANCE.NS's competition here
Cohance Lifesciences Limited (BSE: COHANCE.BO)
GLAND.BO vs COHANCE.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, COHANCE.BO has a market cap of 181.5B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while COHANCE.BO trades at ₹462.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas COHANCE.BO's P/E ratio is 150.25. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to COHANCE.BO's ROE of +0.03%. Regarding short-term risk, GLAND.BO is less volatile compared to COHANCE.BO. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check COHANCE.BO's competition here
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS)
GLAND.BO vs ALIVUS.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, ALIVUS.NS has a market cap of 165.8B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while ALIVUS.NS trades at ₹1,350.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas ALIVUS.NS's P/E ratio is 26.78. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to ALIVUS.NS's ROE of +0.20%. Regarding short-term risk, GLAND.BO is less volatile compared to ALIVUS.NS. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check ALIVUS.NS's competition here
Alivus Life Sciences Limited (BSE: ALIVUS.BO)
GLAND.BO vs ALIVUS.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, ALIVUS.BO has a market cap of 165.5B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while ALIVUS.BO trades at ₹1,348.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas ALIVUS.BO's P/E ratio is 30.00. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to ALIVUS.BO's ROE of +0.10%. Regarding short-term risk, GLAND.BO is less volatile compared to ALIVUS.BO. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check ALIVUS.BO's competition here
Alembic Pharmaceuticals Limited (NSE: APLLTD.NS)
GLAND.BO vs APLLTD.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, APLLTD.NS has a market cap of 161.5B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while APLLTD.NS trades at ₹821.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas APLLTD.NS's P/E ratio is 21.51. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to APLLTD.NS's ROE of +0.13%. Regarding short-term risk, GLAND.BO is more volatile compared to APLLTD.NS. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check APLLTD.NS's competition here
Alembic Pharmaceuticals Limited (BSE: APLLTD.BO)
GLAND.BO vs APLLTD.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, APLLTD.BO has a market cap of 161.3B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while APLLTD.BO trades at ₹820.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas APLLTD.BO's P/E ratio is 21.48. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to APLLTD.BO's ROE of +0.13%. Regarding short-term risk, GLAND.BO is more volatile compared to APLLTD.BO. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check APLLTD.BO's competition here
Shilpa Medicare Limited (NSE: SHILPAMED.NS)
GLAND.BO vs SHILPAMED.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, SHILPAMED.NS has a market cap of 159.4B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while SHILPAMED.NS trades at ₹814.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas SHILPAMED.NS's P/E ratio is 51.78. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to SHILPAMED.NS's ROE of +0.12%. Regarding short-term risk, GLAND.BO is more volatile compared to SHILPAMED.NS. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check SHILPAMED.NS's competition here
Natco Pharma Limited (NSE: NATCOPHARM.NS)
GLAND.BO vs NATCOPHARM.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, NATCOPHARM.NS has a market cap of 158B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while NATCOPHARM.NS trades at ₹882.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas NATCOPHARM.NS's P/E ratio is 13.80. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to NATCOPHARM.NS's ROE of +0.13%. Regarding short-term risk, GLAND.BO is more volatile compared to NATCOPHARM.NS. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check NATCOPHARM.NS's competition here
NATCO Pharma Limited (BSE: NATCOPHARM.BO)
GLAND.BO vs NATCOPHARM.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, NATCOPHARM.BO has a market cap of 158B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while NATCOPHARM.BO trades at ₹882.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas NATCOPHARM.BO's P/E ratio is 13.81. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to NATCOPHARM.BO's ROE of +0.13%. Regarding short-term risk, GLAND.BO is more volatile compared to NATCOPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check NATCOPHARM.BO's competition here
Jubilant Pharmova Limited (NSE: JUBLPHARMA.NS)
GLAND.BO vs JUBLPHARMA.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, JUBLPHARMA.NS has a market cap of 139.4B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while JUBLPHARMA.NS trades at ₹880.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas JUBLPHARMA.NS's P/E ratio is 36.48. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to JUBLPHARMA.NS's ROE of +0.05%. Regarding short-term risk, GLAND.BO is more volatile compared to JUBLPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check JUBLPHARMA.NS's competition here
Jubilant Pharmova Limited (BSE: JUBLPHARMA.BO)
GLAND.BO vs JUBLPHARMA.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, JUBLPHARMA.BO has a market cap of 139.4B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while JUBLPHARMA.BO trades at ₹879.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas JUBLPHARMA.BO's P/E ratio is 36.48. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to JUBLPHARMA.BO's ROE of +0.05%. Regarding short-term risk, GLAND.BO is more volatile compared to JUBLPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check JUBLPHARMA.BO's competition here
Glenmark Life Sciences Limited (NSE: GLS.NS)
GLAND.BO vs GLS.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while GLS.NS trades at ₹1,086.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to GLS.NS's ROE of +0.21%. Regarding short-term risk, GLAND.BO is less volatile compared to GLS.NS. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check GLS.NS's competition here
Glenmark Life Sciences Limited (BSE: GLS.BO)
GLAND.BO vs GLS.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while GLS.BO trades at ₹1,085.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to GLS.BO's ROE of +0.21%. Regarding short-term risk, GLAND.BO is less volatile compared to GLS.BO. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check GLS.BO's competition here
Sudeep Pharma Ltd. (NSE: SUDEEPPHRM.NS)
GLAND.BO vs SUDEEPPHRM.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, SUDEEPPHRM.NS has a market cap of 125.6B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while SUDEEPPHRM.NS trades at ₹1,111.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas SUDEEPPHRM.NS's P/E ratio is 128.53. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to SUDEEPPHRM.NS's ROE of N/A. Regarding short-term risk, GLAND.BO is less volatile compared to SUDEEPPHRM.NS. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check SUDEEPPHRM.NS's competition here
Viyash Scientific Limited (NSE: VIYASH.NS)
GLAND.BO vs VIYASH.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, VIYASH.NS has a market cap of 120.4B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while VIYASH.NS trades at ₹275.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas VIYASH.NS's P/E ratio is 66.33. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to VIYASH.NS's ROE of +0.13%. Regarding short-term risk, GLAND.BO is less volatile compared to VIYASH.NS. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check VIYASH.NS's competition here
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS)
GLAND.BO vs AKUMS.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, AKUMS.NS has a market cap of 114.8B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while AKUMS.NS trades at ₹750.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas AKUMS.NS's P/E ratio is 39.70. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to AKUMS.NS's ROE of +0.09%. Regarding short-term risk, GLAND.BO is more volatile compared to AKUMS.NS. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check AKUMS.NS's competition here
Caplin Point Laboratories Limited (BSE: CAPPL.BO)
GLAND.BO vs CAPPL.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while CAPPL.BO trades at ₹1,446.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, GLAND.BO is less volatile compared to CAPPL.BO. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check CAPPL.BO's competition here
Procter & Gamble Health Limited (BSE: PGHL.BO)
GLAND.BO vs PGHL.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, PGHL.BO has a market cap of 97B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while PGHL.BO trades at ₹5,834.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas PGHL.BO's P/E ratio is 29.64. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to PGHL.BO's ROE of +0.59%. Regarding short-term risk, GLAND.BO is more volatile compared to PGHL.BO. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check PGHL.BO's competition here
Procter & Gamble Health Limited (NSE: PGHL.NS)
GLAND.BO vs PGHL.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, PGHL.NS has a market cap of 96.7B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while PGHL.NS trades at ₹5,828.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas PGHL.NS's P/E ratio is 29.61. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to PGHL.NS's ROE of +0.59%. Regarding short-term risk, GLAND.BO is more volatile compared to PGHL.NS. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check PGHL.NS's competition here
Strides Pharma Science Limited (NSE: STAR.NS)
GLAND.BO vs STAR.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, STAR.NS has a market cap of 90.9B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while STAR.NS trades at ₹986.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas STAR.NS's P/E ratio is 14.83. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to STAR.NS's ROE of +0.22%. Regarding short-term risk, GLAND.BO is less volatile compared to STAR.NS. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check STAR.NS's competition here
Strides Pharma Science Limited (BSE: STAR.BO)
GLAND.BO vs STAR.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, STAR.BO has a market cap of 90.6B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while STAR.BO trades at ₹985.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas STAR.BO's P/E ratio is 14.83. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to STAR.BO's ROE of +0.22%. Regarding short-term risk, GLAND.BO is less volatile compared to STAR.BO. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check STAR.BO's competition here
Suven Life Sciences Limited (NSE: SUVEN.NS)
GLAND.BO vs SUVEN.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, SUVEN.NS has a market cap of 85.1B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while SUVEN.NS trades at ₹373.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas SUVEN.NS's P/E ratio is -30.94. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to SUVEN.NS's ROE of -1.12%. Regarding short-term risk, GLAND.BO is less volatile compared to SUVEN.NS. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check SUVEN.NS's competition here
Suven Life Sciences Limited (BSE: SUVEN.BO)
GLAND.BO vs SUVEN.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, SUVEN.BO has a market cap of 83.9B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while SUVEN.BO trades at ₹372.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas SUVEN.BO's P/E ratio is -30.01. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to SUVEN.BO's ROE of -1.12%. Regarding short-term risk, GLAND.BO is less volatile compared to SUVEN.BO. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check SUVEN.BO's competition here
Shilpa Medicare Limited (BSE: SHILPAMED.BO)
GLAND.BO vs SHILPAMED.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, SHILPAMED.BO has a market cap of 79.7B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while SHILPAMED.BO trades at ₹814.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas SHILPAMED.BO's P/E ratio is 53.44. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to SHILPAMED.BO's ROE of +0.12%. Regarding short-term risk, GLAND.BO is more volatile compared to SHILPAMED.BO. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check SHILPAMED.BO's competition here
Aarti Pharmalabs Limited (NSE: AARTIPHARM.NS)
GLAND.BO vs AARTIPHARM.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, AARTIPHARM.NS has a market cap of 74.1B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while AARTIPHARM.NS trades at ₹816.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas AARTIPHARM.NS's P/E ratio is 28.23. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to AARTIPHARM.NS's ROE of +0.10%. Regarding short-term risk, GLAND.BO is less volatile compared to AARTIPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check AARTIPHARM.NS's competition here
Aarti Pharmalabs Limited (BSE: AARTIPHARM.BO)
GLAND.BO vs AARTIPHARM.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, AARTIPHARM.BO has a market cap of 73.7B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while AARTIPHARM.BO trades at ₹816.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas AARTIPHARM.BO's P/E ratio is 39.41. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to AARTIPHARM.BO's ROE of +0.10%. Regarding short-term risk, GLAND.BO is less volatile compared to AARTIPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check AARTIPHARM.BO's competition here
Sun Pharma Advanced Research Company Limited (NSE: SPARC.NS)
GLAND.BO vs SPARC.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, SPARC.NS has a market cap of 63.8B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while SPARC.NS trades at ₹196.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas SPARC.NS's P/E ratio is 4.11. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to SPARC.NS's ROE of +3.19%. Regarding short-term risk, GLAND.BO is more volatile compared to SPARC.NS. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check SPARC.NS's competition here
Sun Pharma Advanced Research Company Limited (BSE: SPARC.BO)
GLAND.BO vs SPARC.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, SPARC.BO has a market cap of 63.7B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while SPARC.BO trades at ₹196.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas SPARC.BO's P/E ratio is 4.11. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to SPARC.BO's ROE of +3.19%. Regarding short-term risk, GLAND.BO is more volatile compared to SPARC.BO. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check SPARC.BO's competition here
Innova Captab Limited (NSE: INNOVACAP.NS)
GLAND.BO vs INNOVACAP.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, INNOVACAP.NS has a market cap of 62.3B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while INNOVACAP.NS trades at ₹1,088.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas INNOVACAP.NS's P/E ratio is 51.18. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to INNOVACAP.NS's ROE of +0.15%. Regarding short-term risk, GLAND.BO is more volatile compared to INNOVACAP.NS. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check INNOVACAP.NS's competition here
Bliss GVS Pharma Limited (BSE: BLISSGVS.BO)
GLAND.BO vs BLISSGVS.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, BLISSGVS.BO has a market cap of 62.1B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while BLISSGVS.BO trades at ₹582.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas BLISSGVS.BO's P/E ratio is 48.32. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to BLISSGVS.BO's ROE of +0.12%. Regarding short-term risk, GLAND.BO is less volatile compared to BLISSGVS.BO. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check BLISSGVS.BO's competition here
Bliss GVS Pharma Limited (NSE: BLISSGVS.NS)
GLAND.BO vs BLISSGVS.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, BLISSGVS.NS has a market cap of 61.4B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while BLISSGVS.NS trades at ₹579.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas BLISSGVS.NS's P/E ratio is 48.06. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to BLISSGVS.NS's ROE of +0.12%. Regarding short-term risk, GLAND.BO is less volatile compared to BLISSGVS.NS. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check BLISSGVS.NS's competition here
FDC Limited (NSE: FDC.NS)
GLAND.BO vs FDC.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, FDC.NS has a market cap of 56.8B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while FDC.NS trades at ₹348.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas FDC.NS's P/E ratio is 20.16. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to FDC.NS's ROE of +0.12%. Regarding short-term risk, GLAND.BO is more volatile compared to FDC.NS. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check FDC.NS's competition here
FDC Limited (BSE: FDC.BO)
GLAND.BO vs FDC.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, FDC.BO has a market cap of 56.7B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while FDC.BO trades at ₹348.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas FDC.BO's P/E ratio is 20.14. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to FDC.BO's ROE of +0.12%. Regarding short-term risk, GLAND.BO is more volatile compared to FDC.BO. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check FDC.BO's competition here
Morepen Laboratories Limited (BSE: MOREPENLAB.BO)
GLAND.BO vs MOREPENLAB.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, MOREPENLAB.BO has a market cap of 52.6B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while MOREPENLAB.BO trades at ₹96.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas MOREPENLAB.BO's P/E ratio is 55.49. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to MOREPENLAB.BO's ROE of +0.12%. Regarding short-term risk, GLAND.BO is less volatile compared to MOREPENLAB.BO. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check MOREPENLAB.BO's competition here
Morepen Laboratories Limited (NSE: MOREPENLAB.NS)
GLAND.BO vs MOREPENLAB.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, MOREPENLAB.NS has a market cap of 52.6B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while MOREPENLAB.NS trades at ₹96.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas MOREPENLAB.NS's P/E ratio is 55.50. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to MOREPENLAB.NS's ROE of +0.12%. Regarding short-term risk, GLAND.BO is less volatile compared to MOREPENLAB.NS. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check MOREPENLAB.NS's competition here
Orchid Pharma Limited (NSE: ORCHPHARMA.NS)
GLAND.BO vs ORCHPHARMA.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, ORCHPHARMA.NS has a market cap of 50.8B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while ORCHPHARMA.NS trades at ₹1,002.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas ORCHPHARMA.NS's P/E ratio is 161.62. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to ORCHPHARMA.NS's ROE of +0.01%. Regarding short-term risk, GLAND.BO is less volatile compared to ORCHPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check ORCHPHARMA.NS's competition here
Sequent Scientific Limited (BSE: SEQUENT.BO)
GLAND.BO vs SEQUENT.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while SEQUENT.BO trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to SEQUENT.BO's ROE of +0.09%. Regarding short-term risk, GLAND.BO is less volatile compared to SEQUENT.BO. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check SEQUENT.BO's competition here
Sequent Scientific Limited (NSE: SEQUENT.NS)
GLAND.BO vs SEQUENT.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while SEQUENT.NS trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to SEQUENT.NS's ROE of +0.09%. Regarding short-term risk, GLAND.BO is less volatile compared to SEQUENT.NS. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check SEQUENT.NS's competition here
Orchid Pharma Limited (BSE: ORCHPHARMA.BO)
GLAND.BO vs ORCHPHARMA.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, ORCHPHARMA.BO has a market cap of 50.5B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while ORCHPHARMA.BO trades at ₹997.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas ORCHPHARMA.BO's P/E ratio is 77.68. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to ORCHPHARMA.BO's ROE of +0.01%. Regarding short-term risk, GLAND.BO is less volatile compared to ORCHPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check ORCHPHARMA.BO's competition here
IOL Chemicals and Pharmaceuticals Limited (BSE: IOLCP.BO)
GLAND.BO vs IOLCP.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, IOLCP.BO has a market cap of 49.8B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while IOLCP.BO trades at ₹169.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas IOLCP.BO's P/E ratio is 33.25. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to IOLCP.BO's ROE of +0.10%. Regarding short-term risk, GLAND.BO is less volatile compared to IOLCP.BO. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check IOLCP.BO's competition here
IOL Chemicals and Pharmaceuticals Limited (NSE: IOLCP.NS)
GLAND.BO vs IOLCP.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, IOLCP.NS has a market cap of 49.8B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while IOLCP.NS trades at ₹169.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas IOLCP.NS's P/E ratio is 33.37. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to IOLCP.NS's ROE of +0.10%. Regarding short-term risk, GLAND.BO is less volatile compared to IOLCP.NS. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check IOLCP.NS's competition here
RPG Life Sciences Limited (BSE: RPGLIFE.BO)
GLAND.BO vs RPGLIFE.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, RPGLIFE.BO has a market cap of 43.9B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while RPGLIFE.BO trades at ₹2,634.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas RPGLIFE.BO's P/E ratio is 37.83. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to RPGLIFE.BO's ROE of +0.21%. Regarding short-term risk, GLAND.BO is more volatile compared to RPGLIFE.BO. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check RPGLIFE.BO's competition here
RPG Life Sciences Limited (NSE: RPGLIFE.NS)
GLAND.BO vs RPGLIFE.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, RPGLIFE.NS has a market cap of 43.6B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while RPGLIFE.NS trades at ₹2,636.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas RPGLIFE.NS's P/E ratio is 37.86. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to RPGLIFE.NS's ROE of +0.21%. Regarding short-term risk, GLAND.BO is more volatile compared to RPGLIFE.NS. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check RPGLIFE.NS's competition here
Gufic Biosciences Limited (BSE: GUFICBIO.BO)
GLAND.BO vs GUFICBIO.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, GUFICBIO.BO has a market cap of 43.4B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while GUFICBIO.BO trades at ₹432.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas GUFICBIO.BO's P/E ratio is 67.64. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to GUFICBIO.BO's ROE of +0.11%. Regarding short-term risk, GLAND.BO is less volatile compared to GUFICBIO.BO. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check GUFICBIO.BO's competition here
Gufic Biosciences Limited (NSE: GUFICBIO.NS)
GLAND.BO vs GUFICBIO.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, GUFICBIO.NS has a market cap of 43.3B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while GUFICBIO.NS trades at ₹431.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas GUFICBIO.NS's P/E ratio is 67.42. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to GUFICBIO.NS's ROE of +0.11%. Regarding short-term risk, GLAND.BO is less volatile compared to GUFICBIO.NS. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check GUFICBIO.NS's competition here
Gujarat Themis Biosyn Ltd. (NSE: GUJTHEM.NS)
GLAND.BO vs GUJTHEM.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, GUJTHEM.NS has a market cap of 41.5B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while GUJTHEM.NS trades at ₹381.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas GUJTHEM.NS's P/E ratio is 88.65. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to GUJTHEM.NS's ROE of +0.18%. Regarding short-term risk, GLAND.BO is less volatile compared to GUJTHEM.NS. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check GUJTHEM.NS's competition here
Gujarat Themis Biosyn Limited (BSE: GUJTHEM.BO)
GLAND.BO vs GUJTHEM.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, GUJTHEM.BO has a market cap of 41.5B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while GUJTHEM.BO trades at ₹380.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas GUJTHEM.BO's P/E ratio is 29.35. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to GUJTHEM.BO's ROE of +0.18%. Regarding short-term risk, GLAND.BO is less volatile compared to GUJTHEM.BO. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check GUJTHEM.BO's competition here
Aarti Drugs Limited (BSE: AARTIDRUGS.BO)
GLAND.BO vs AARTIDRUGS.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, AARTIDRUGS.BO has a market cap of 38.1B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while AARTIDRUGS.BO trades at ₹417.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas AARTIDRUGS.BO's P/E ratio is 19.66. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to AARTIDRUGS.BO's ROE of +0.13%. Regarding short-term risk, GLAND.BO is more volatile compared to AARTIDRUGS.BO. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check AARTIDRUGS.BO's competition here
Aarti Drugs Limited (NSE: AARTIDRUGS.NS)
GLAND.BO vs AARTIDRUGS.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, AARTIDRUGS.NS has a market cap of 38.1B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while AARTIDRUGS.NS trades at ₹417.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas AARTIDRUGS.NS's P/E ratio is 19.64. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to AARTIDRUGS.NS's ROE of +0.13%. Regarding short-term risk, GLAND.BO is more volatile compared to AARTIDRUGS.NS. This indicates higher risk in terms of short-term price fluctuations for GLAND.BO.Check AARTIDRUGS.NS's competition here
Unichem Laboratories Limited (BSE: UNICHEMLAB.BO)
GLAND.BO vs UNICHEMLAB.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, UNICHEMLAB.BO has a market cap of 37.1B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while UNICHEMLAB.BO trades at ₹525.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas UNICHEMLAB.BO's P/E ratio is 14.64. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to UNICHEMLAB.BO's ROE of +0.12%. Regarding short-term risk, GLAND.BO is less volatile compared to UNICHEMLAB.BO. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check UNICHEMLAB.BO's competition here
Unichem Laboratories Limited (NSE: UNICHEMLAB.NS)
GLAND.BO vs UNICHEMLAB.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, UNICHEMLAB.NS has a market cap of 37B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while UNICHEMLAB.NS trades at ₹526.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas UNICHEMLAB.NS's P/E ratio is 14.65. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to UNICHEMLAB.NS's ROE of +0.12%. Regarding short-term risk, GLAND.BO is less volatile compared to UNICHEMLAB.NS. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check UNICHEMLAB.NS's competition here
Novartis India Limited (BSE: NOVARTIND.BO)
GLAND.BO vs NOVARTIND.BO Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, NOVARTIND.BO has a market cap of 35.1B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while NOVARTIND.BO trades at ₹1,423.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas NOVARTIND.BO's P/E ratio is 37.04. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to NOVARTIND.BO's ROE of +0.12%. Regarding short-term risk, GLAND.BO is less volatile compared to NOVARTIND.BO. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check NOVARTIND.BO's competition here
Novartis India Limited (NSE: NOVARTIND.NS)
GLAND.BO vs NOVARTIND.NS Comparison August 2026
Gland Pharma Limited (BSE: GLAND.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAND.BO stands at 465B. In comparison, NOVARTIND.NS has a market cap of 35B. Regarding current trading prices, GLAND.BO is priced at ₹2,820.40 on the BSE, while NOVARTIND.NS trades at ₹1,418.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAND.BO currently has a P/E ratio of 41.15, whereas NOVARTIND.NS's P/E ratio is 36.92. In terms of profitability, GLAND.BO's ROE is +0.11%, compared to NOVARTIND.NS's ROE of +0.12%. Regarding short-term risk, GLAND.BO is less volatile compared to NOVARTIND.NS. This indicates lower risk in terms of short-term price fluctuations for GLAND.BO.Check NOVARTIND.NS's competition here